サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：サラセミアの世界市場 - 市場シェア・規模・動向・業界分析：治療タイプ別、最終用途別、疾患タイプ別、地域別、セグメント予測（2022年～2030年）
市場調査レポート
商品コード
1150075

サラセミアの世界市場 - 市場シェア・規模・動向・業界分析：治療タイプ別、最終用途別、疾患タイプ別、地域別、セグメント予測（2022年～2030年）

Thalassemia Market Share, Size, Trends, Industry Analysis Report, By Treatment Type (Iron Chelating Drugs, Blood Transfusions, Folic Acid Supplements, Gene Therapy, Others); By End-Use; By Disease Type; By Region; Segment Forecast, 2022 - 2030
出版日: | 発行: Polaris Market Research | ページ情報: 英文 117 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
サラセミアの世界市場 - 市場シェア・規模・動向・業界分析：治療タイプ別、最終用途別、疾患タイプ別、地域別、セグメント予測（2022年～2030年）
出版日: 2022年10月01日
発行: Polaris Market Research
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のサラセミアの市場規模は、2030年までに1兆4,929億米ドルに達すると予測されています。

当レポートでは、世界のサラセミア市場を調査しており、市場の概要、市場規模や予測、動向、促進要因・抑制要因、治療タイプ別・最終用途別・疾患タイプ別・地域別などの分析、さらに企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

  • レポートの説明
    • 調査の目的
    • 市場範囲
    • 前提条件
  • 利害関係者

第2章 エグゼクティブサマリー

  • 市場のハイライト

第3章 調査手法

  • 概要
    • データマイニング
  • 情報源
    • 一次情報
    • 二次情報

第4章 世界のサラセミア市場の洞察

  • サラセミア - 業界のスナップショット
  • サラセミア市場力学
    • 促進要因と機会
    • 抑制要因と課題
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 新規参入者の脅威
    • 買い手の交渉力
    • 代替品の脅威
    • 既存企業間の競争力
  • PESTEL分析
  • サラセミア市場の業界動向
  • バリューチェーン分析
  • COVID-19影響分析

第5章 世界のサラセミア市場：治療タイプ別

  • 主な調査結果
  • イントロダクション
    • 世界のサラセミア市場、治療タイプ別（2018年～2030年）
  • 鉄キレート剤
    • 世界のサラセミア市場、鉄キレート剤別、地域別（2018年～2030年）
  • 輸血
    • 世界のサラセミア市場、輸血別、地域別（2018年～2030年）
  • 葉酸サプリメント
    • 世界のサラセミア市場、葉酸サプリメント別、地域別（2018年～2030年）
  • 遺伝子治療
    • 世界のサラセミア市場、遺伝子治療別、地域別（2018年～2030年）
  • その他
    • 世界のサラセミア市場、その他別、地域別（2018年～2030年）

第6章 世界のサラセミア市場：疾患タイプ別

  • 主な調査結果
  • イントロダクション
    • 世界のサラセミア市場、疾患タイプ別（2018年～2030年）
  • アルファ
    • 世界のサラセミア市場、アルファ別、地域別（2018年～2030年）
  • ベータ
    • 世界のサラセミア市場、ベータ別、地域別（2018年～2030年）

第7章 世界のサラセミア市場：最終用途別

  • 主な調査結果
  • イントロダクション
    • 世界のサラセミア市場、最終用途別（2018年～2030年）
  • 病院
    • 世界のサラセミア市場、病院別、地域別（2018年～2030年）
  • 研究機関
    • 世界のサラセミア市場、研究機関別、地域別（2018年～2030年）
  • その他
    • 世界のサラセミア市場、その他別、地域別（2018年～2030年）

第8章 世界のサラセミア市場：地域別

  • 主な調査結果
  • イントロダクション
    • 地域市場の評価、地域別（2018年～2030年）
  • サラセミア市場 - 北米
    • 北米：サラセミア市場、治療タイプ別（2018年～2030年）
    • 北米：サラセミア市場、最終用途別（2018年～2030年）
    • 北米：サラセミア市場、疾患タイプ別（2018年～2030年）
    • サラセミア市場 - 米国
    • サラセミア市場 - カナダ
  • サラセミア市場 - 欧州
    • 欧州：サラセミア市場、治療タイプ別（2018年～2030年）
    • 欧州：サラセミア市場、最終用途別（2018年～2030年）
    • 欧州：サラセミア市場、疾患タイプ別（2018年～2030年）
    • サラセミア市場 - 英国
    • サラセミア市場 - フランス
    • サラセミア市場 - ドイツ
    • サラセミア市場 - イタリア
    • サラセミア市場 - スペイン
    • サラセミア市場 - オランダ
    • サラセミア市場 - ロシア
  • サラセミア市場 - アジア太平洋
    • アジア太平洋：サラセミア市場、治療タイプ別（2018年～2030年）
    • アジア太平洋：サラセミア市場、最終用途別（2018年～2030年）
    • アジア太平洋：サラセミア市場、疾患タイプ別（2018年～2030年）
    • サラセミア市場 - 中国
    • サラセミア市場 - インド
    • サラセミア市場 - マレーシア
    • サラセミア市場 - 日本
    • サラセミア市場 - インドネシア
    • サラセミア市場 - 韓国
  • サラセミア市場 - 中東・アフリカ
    • 中東・アフリカ：サラセミア市場、治療タイプ別（2018年～2030年）
    • 中東・アフリカ：サラセミア市場、最終用途別（2018年～2030年）
    • 中東・アフリカ：サラセミア市場、疾患タイプ別（2018年～2030年）
    • サラセミア市場 - サウジアラビア
    • サラセミア市場 - アラブ首長国連邦
    • サラセミア市場 - イスラエル
    • サラセミア市場 - 南アフリカ
  • サラセミア市場 - ラテンアメリカ
    • ラテンアメリカ：サラセミア市場、治療タイプ別（2018年～2030年）
    • ラテンアメリカ：サラセミア市場、最終用途別（2018年～2030年）
    • ラテンアメリカ：サラセミア市場、疾患タイプ別（2018年～2030年）
    • サラセミア市場 - メキシコ
    • サラセミア市場 - ブラジル
    • サラセミア市場 - アルゼンチン

第9章 競合情勢

  • 拡大・買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/協定/公開

第10章 企業プロファイル

  • ApoPharma Inc.
  • Acceleron Pharma, Inc.
  • Bluebird Bio Corporation
  • Bellicum Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • IONIS Pharmaceuticals
  • Kiadis Pharma
  • Lonza Group Ltd.
  • La Jolla Pharmaceutical Company
  • Novartis AG
  • Pfizer, Inc.
  • SG Pharma Pvt. Lmt.
  • Sangamo Therapeutics
  • Vifor Pharma
図表

List of Tables

  • Table 1 Global Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 2 Global Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 3 Global Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 4 Thalassemia Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • Table 5 North America: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 6 North America: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 7 North America: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 8 U.S.: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 9 U.S.: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 10 U.S.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 11 Canada: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 12 Canada: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 13 Canada: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 14 Europe: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 15 Europe: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 16 Europe: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 17 UK: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 18 UK: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 19 UK: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 20 France: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 21 France: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 22 France: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 23 Germany: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 24 Germany: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 25 Germany: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 26 Italy: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 27 Italy: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 28 Italy: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 29 Spain: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 30 Spain: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 31 Spain: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 32 Netherlands: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 33 Netherlands: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 34 Netherlands: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 35 Russia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 36 Russia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 37 Russia: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 38 Asia Pacific: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 39 Asia Pacific: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 40 Asia Pacific: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 41 China: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 42 China: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 43 China: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 44 India: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 45 India: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 46 India: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 47 Malaysia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 48 Malaysia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 49 Malaysia: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 50 Japan: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 51 Japan: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 52 Japan: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 53 Indonesia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 54 Indonesia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 55 Indonesia: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 56 South Korea: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 57 South Korea: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 58 South Korea: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 59 Middle East & Africa: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 60 Middle East & Africa: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 61 Middle East & Africa: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 62 Saudi Arabia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 63 Saudi Arabia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 64 Saudi Arabia: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 65 UAE: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 66 UAE: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 67 UAE: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 68 Israel: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 69 Israel: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 70 Israel: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 71 South Africa: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 72 South Africa: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 73 South Africa: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 74 Latin America: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 75 Latin America: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 76 Latin America: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 77 Mexico: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 78 Mexico: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 79 Mexico: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 80 Brazil: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 81 Brazil: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 82 Brazil: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 83 Argentina: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 84 Argentina: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 85 Argentina: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)

List of Figures

Figure 1. Global Thalassemia Market, 2018 - 2030 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Approach

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Disease Type

Figure 7. Global Thalassemia Market, by Disease Type, 2021 & 2030 (USD Billion)

Figure 8. Market by Treatment Type

Figure 9. Global Thalassemia Market, by Treatment Type, 2021 & 2030 (USD Billion)

Figure 10. Market by End-Use

Figure 11. Global Thalassemia Market, by End-Use, 2021 & 2030 (USD Billion)

Figure 12. Thalassemia Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 13. Strategic Analysis - Thalassemia Market

目次
Product Code: PM1377

The global thalassemia market size is expected to reach USD 1,492.9 billion by 2030, according to a new study by Polaris Market Research. The report "Thalassemia Market Share, Size, Trends, Industry Analysis Report, By Treatment Type (Iron Chelating Drugs, Blood Transfusions, Folic Acid Supplements, Gene Therapy, and Others); By Disease Type; By End-Use; By Region; Segment Forecast, 2022-2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The primary drivers driving market growth include rising thalassemia prevalence and increased thalassemia treatment awareness. According to the National Institute Health study report states that as per the Thalassemia International Federation, roughly 7.0% of the world's population suffers from hemoglobin-based diseases and conditions, with approximately 70.0% having sickle cell anemia and the remainder developing thalassemia. Thalassemia affects around 2.1% of the world's population.

Furthermore, as per the Medical Science Study, thalassemia affects roughly 4.4 out of every 10,000 live births worldwide. Since it maintains an autosomal mode of inheritance with no predilection for gender, either males or females receive the relevant gene variants equally. Approximately 5% of the global population possesses a variant in the alpha or beta component of the hemoglobin molecule. Just 1.7% of the world's population has symptoms caused by genetic mutations, which are classified as a thalassemia trait.

However, certain ethnic groups are more prone to be affected, with 5% to 30% of these populations suffering thalassemia indications. Thus, the rising prevalence of the disease has led to an increase in the demand for treatment which is boosting the market growth over the forecast period.

Moreover, the availability of therapies for the treatment of disease with its benefits is boosting the market growth over the forecast period. Chelation therapy and blood transfusions are the most common therapies for thalassemia patients because they are less expensive and more widely available than bone marrow transplants.

Chelation therapy employs medications such as widely prescribed to treat chronic iron overload that occurs following many blood transfusions in people with chronic thalassemia. Chelation therapy medicines used subcutaneously or intravenously using a gradual infusion approach to purify blood improve patients' chances of curing thalassemia. However, the expensive cost of the treatment is a key impediment to market growth.

Thalassemia Market Report Highlights

Blood Transfusions segment is anticipated to grow at a significant CAGR over the forecast period. The expanding market for marrow transplant and blood transfusion therapy, the increasing number of transfusion-dependent patients, and the realization of affordable treatment methods for thalassemia is projected to fuel market expansion.

gene therapy segment accounted for the largest share of the global revenue due to the rise in prevalence of thalassemia disease across the globe.

Asia Pacific is expected to grow at a witness fastest growth over the projected period. The existence of a substantial number of sickle cell disease and thalassemia patients is projected to drive market expansion in the coming years. Supportive government measures targeted at increasing the standard of care provided to individuals with hemoglobinopathies are supporting the region's market growth.

The global market includes ApoPharma Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, IONIS Pharmaceuticals, Kiadis Pharma, La Jolla Pharmaceutical Company, Novartis AG, Pfizer, Inc., SG Pharma Pvt. Lmt., Sangamo Therapeutics, and Vifor Pharma

Polaris Market Research has segmented the Thalassemia market report based on treatment type, disease type, end-user, and region:

Thalassemia, Treatment Type Outlook (Revenue - USD Billion, 2018 - 2030)

Iron Chelating Drugs

Blood Transfusions

Folic Acid Supplements

Gene Therapy

Others

Thalassemia, Disease Type Outlook (Revenue - USD Billion, 2018 - 2030)

Alpha Thalassemia

Beta Thalassemia

Thalassemia, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital

Research Institute

Others

Thalassemia, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Thalassemia Market Insights

  • 4.1. Thalassemia - Industry Snapshot
  • 4.2. Thalassemia Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Prevalence of Thalassemia
      • 4.2.1.2. Increasing Awareness of Thalassemia Treatment
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Treatment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Thalassemia Market Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Thalassemia Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • 5.3. Iron Chelating Drugs
    • 5.3.1. Global Thalassemia Market, by Iron Chelating Drugs, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Blood Transfusions
    • 5.4.1. Global Thalassemia Market, by Blood Transfusions, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Folic Acid Supplements
    • 5.5.1. Global Thalassemia Market, by Folic Acid Supplements, by Region, 2018 - 2030 (USD Billion)
  • 5.6. Gene Therapy
    • 5.6.1. Global Thalassemia Market, by Gene Therapy, by Region, 2018 - 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Thalassemia Market, by Others, by Region, 2018 - 2030 (USD Billion)

6. Global Thalassemia Market, by Disease Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 6.3. Alpha
    • 6.3.1. Global Thalassemia Market, by Alpha, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Beta
    • 6.4.1. Global Thalassemia Market, by Beta, by Region, 2018 - 2030 (USD Billion)

7. Global Thalassemia Market, by End-Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
  • 7.3. Hospital
    • 7.3.1. Global Thalassemia Market, by Hospital, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Research Institute
    • 7.4.1. Global Thalassemia Market, by Research Institute, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Thalassemia Market, by Others, by Region, 2018 - 2030 (USD Billion)

8. Global Thalassemia Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Thalassemia Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 8.3. Thalassemia Market - North America
    • 8.3.1. North America: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.3.2. North America: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.3.3. North America: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.3.4. Thalassemia Market - U.S.
      • 8.3.4.1. U.S.: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.3.4.2. U.S.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.3.4.3. U.S.: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.3.5. Thalassemia Market - Canada
      • 8.3.5.1. Canada: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.3.5.2. Canada.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.3.5.3. Canada: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.4. Thalassemia Market - Europe
    • 8.4.1. Europe: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.4.2. Europe.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.4.3. Europe: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.4. Thalassemia Market - UK
      • 8.4.4.1. UK: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.4.2. UK.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.4.3. UK: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.5. Thalassemia Market - France
      • 8.4.5.1. France: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.5.2. France.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.5.3. France: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.6. Thalassemia Market - Germany
      • 8.4.6.1. Germany: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.6.2. Germany.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.6.3. Germany: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.7. Thalassemia Market - Italy
      • 8.4.7.1. Italy: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.7.2. Italy.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.7.3. Italy: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.8. Thalassemia Market - Spain
      • 8.4.8.1. Spain: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.8.2. Spain.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.8.3. Spain: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.9. Thalassemia Market - Netherlands
      • 8.4.9.1. Netherlands: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.9.2. Netherlands.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.9.3. Netherlands: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.10. Thalassemia Market - Russia
      • 8.4.10.1. Russia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.4.10.2. Russia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.10.3. Russia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.5. Thalassemia Market - Asia Pacific
    • 8.5.1. Asia Pacific: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.5.2. Asia Pacific.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.5.3. Asia Pacific: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.4. Thalassemia Market - China
      • 8.5.4.1. China: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.4.2. China.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.4.3. China: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.5. Thalassemia Market - India
      • 8.5.5.1. India: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.5.2. India.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.5.3. India: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.6. Thalassemia Market - Malaysia
      • 8.5.6.1. Malaysia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.6.2. Malaysia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.6.3. Malaysia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.7. Thalassemia Market - Japan
      • 8.5.7.1. Japan: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.7.2. Japan.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.7.3. Japan: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.8. Thalassemia Market - Indonesia
      • 8.5.8.1. Indonesia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.8.2. Indonesia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.8.3. Indonesia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.9. Thalassemia Market - South Korea
      • 8.5.9.1. South Korea: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.5.9.2. South Korea.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.9.3. South Korea: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.6. Thalassemia Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.6.2. Middle East & Africa.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.6.3. Middle East & Africa: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.6.4. Thalassemia Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.6.5. Thalassemia Market - UAE
      • 8.6.5.1. UAE: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.6.5.2. UAE.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.5.3. UAE: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.6.6. Thalassemia Market - Israel
      • 8.6.6.1. Israel: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.6.6.2. Israel.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.6.3. Israel: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.6.7. Thalassemia Market - South Africa
      • 8.6.7.1. South Africa: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.6.7.2. South Africa.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.7.3. South Africa: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 8.7. Thalassemia Market - Latin America
    • 8.7.1. Latin America: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 8.7.2. Latin America.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.7.3. Latin America: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.7.4. Thalassemia Market - Mexico
      • 8.7.4.1. Mexico: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.7.4.2. Mexico.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.7.4.3. Mexico: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.7.5. Thalassemia Market - Brazil
      • 8.7.5.1. Brazil: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.7.5.2. Brazil.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.7.5.3. Brazil: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.7.6. Thalassemia Market - Argentina
      • 8.7.6.1. Argentina: Thalassemia Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 8.7.6.2. Argentina.: Thalassemia Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.7.6.3. Argentina: Thalassemia Market, by Disease Type, 2018 - 2030 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. ApoPharma Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Acceleron Pharma, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bluebird Bio Corporation
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bellicum Pharmaceuticals
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Teva Pharmaceutical Industries Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Fresenius Kabi AG
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. GlaxoSmithKline plc
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. IONIS Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Kiadis Pharma
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Lonza Group Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. La Jolla Pharmaceutical Company
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Novartis AG
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Pfizer, Inc.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. SG Pharma Pvt. Lmt.
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Sangamo Therapeutics
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development
  • 10.16. Vifor Pharma
    • 10.16.1. Company Overview
    • 10.16.2. Financial Performance
    • 10.16.3. Product Benchmarking
    • 10.16.4. Recent Development